Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for serious cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan. Co.'s programs include: TNX-103 and TNX-102 (levosimendan), a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and TNX-201(imatinib), a tyrosine kinase inhibitor, which changed the treatment of chronic myeloid leukemia. The TENX stock yearly return is shown above.
The yearly return on the TENX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TENX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|